Abbott Laboratories (ABT) announced Thursday it's acquiring cancer screening specialist Exact Sciences Corp (EXAS) for $105 per share, translating to roughly $21 billion in total equity value and an estimated $23 billion enterprise value when you factor in debt. It's the biggest healthcare deal of the year, and it fundamentally reshapes Abbott's diagnostics business at a time when the company has been hunting for its next growth driver.

The star of this acquisition is Cologuard, Exact Sciences' colorectal cancer diagnostic test that's become something of a household name in preventive screening. Since getting FDA approval back in 2014, the test has been used 20 million times, according to Exact Sciences. Now it's Abbott's problem to scale it even further.

Bloomberg originally broke news of the potential deal, and it fits perfectly with what Abbott CEO Robert Ford has been telegraphing for months. During the company's July quarterly results, Ford made it clear that diagnostics M&A was on the table. Abbott's diagnostics business boomed during the pandemic, but sales have cooled since then, and the company has increasingly leaned on its medical device portfolio, particularly its glucose monitors, to drive growth.

The Financial Mechanics

This is Abbott's largest acquisition in nearly a decade and its second-biggest ever. Bloomberg Intelligence analysts noted Wednesday that Abbott could deploy up to $30 billion for debt-financed deals, supported by modest 1.3x leverage and roughly $7 billion in annual free cash flow. The company's financing plan contemplates absorbing Exact Sciences' estimated $1.8 billion in net debt.

William Blair had been modeling what a buyout might look like and suggested a buyer would likely need to pay six to seven times forward sales. That implies a premium of more than 35% to Exact Sciences' current multiple of just under 5x, and about 20% above its five-year average of 5.6x. The firm said this range aligns with valuations of smaller but similarly profitable, high-growth lab peers. Their earlier discounted cash flow analysis suggested a conservative path to $80 per share, but they noted any real acquisition would need to come in well north of $100. At $105, Abbott threaded that needle.

What Abbott Gets

The acquisition adds a new growth vertical to Abbott's high single-digit growth profile, giving it leadership in the fast-growing $60 billion U.S. cancer screening and precision oncology diagnostics segments. Exact Sciences is projected to generate more than $3 billion in revenue in 2025, with an organic sales growth rate in the high teens. Once the deal closes, expected in the second quarter of 2026, Exact Sciences will operate as an Abbott subsidiary, and Abbott's total diagnostics sales will exceed $12 billion annually.

Analyst Andrew F. Brackmann said Wednesday, "We continue to rate shares of both Abbott and Exact Sciences at Outperform. At a minimum for Exact, this should create a valuation floor moving forward as it drives Cologuard growth acceleration and margin expansion into 2026."

Market Reaction

Investors seemed pleased with the deal structure. During Thursday's premarket session, EXAS stock jumped 17.43% to $101.20, still trading a bit below the $105 offer price as the market prices in deal risk and the long close timeline. ABT stock edged up 0.27% to $126.49, suggesting shareholders view the acquisition as reasonably priced rather than a value-destroying overpay.